Imunon

Imunon EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Imunon (IMNN) as of Oct 16, 2026 is -14.65 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -19.13 M USD — a change of -23.42% (higher).

EBITDA

-14.65 MUSD

YoY

-23.42%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Imunon is 2025 -14.65 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Imunon was 2024 -19.13 M USD. It decreases by -23.42% higher compared to the previous year.

The Imunon EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-21.59 M USD
Jan 1, 2019
-20.57 M USD
Jan 1, 2020
-22.04 M USD
Jan 1, 2021
-21.60 M USD
Jan 1, 2022
-32.44 M USD
Jan 1, 2023
-21.03 M USD
Jan 1, 2024
-19.13 M USD
Jan 1, 2025
-14.65 M USD
The Imunon EBITDA history
YEAREBITDAYoY
-14.65 MUSD-23.42%
-19.13 MUSD-9.02%
-21.03 MUSD-35.16%
-32.44 MUSD+50.16%
-21.60 MUSD-1.98%
-22.04 MUSD+7.16%
-20.57 MUSD-4.75%
-21.59 MUSD+16.90%
-18.47 MUSD-10.56%
-20.65 MUSD-0.94%
-20.85 MUSD-15.65%
-24.72 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imunon Stock analysis

What does Imunon do? Imunon Inc is a clinical stage oncology drug company headquartered in Lawrenceville, New Jersey. The company has 31 full-time employees and went public on October 27, 1993. Imunon focuses on developing treatments that leverage the body's natural mechanisms for various diseases. It operates two platform technologies: the TheraPlas platform for immunotherapies and nucleic acid-based anti-cancer therapies, and the PLACCINE platform for nucleic acid vaccines targeting infectious diseases and cancer. The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy designed for localized treatment of advanced ovarian cancer. IMNN-001 functions by prompting the body to generate cancer-fighting molecules like interleukin-12 and interferon gamma directly at the tumor site. Additionally, Imunon is conducting preclinical research on a nucleic acid vaccine candidate against the SARS-CoV-2 virus to validate its PLACCINE platform. The company's technologies rely on synthetic delivery systems for nucleic acids, avoiding viral vectors or devices. Imunon's website is https://imunon.com/ and it is listed under the ticker IMNN with ISIN US15117N7012. The company operates within the health care sector, specifically in biotechnology. Imunon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imunon stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Imunon is -14.65 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Imunon changed from -19.13 M USD to -14.65 M USD, representing a -23.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Imunon since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Imunon historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Imunon

All Key Metrics — Imunon